Asset profile
Elacestrant
Small molecule
Evidence outlook
Approved: HR+/HER2- Metastatic Breast Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
67 competitors in this universe: 7 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Elacestrant: this drug | Approved | Small molecule | Estrogen receptor | ||
| Fulvestrant (Faslodex) | Approved | Small molecule | Estrogen receptor | ||
| Imlunestrant | Approved | Small molecule | Estrogen receptor | ||
| Tamoxifen | Approved | Small molecule | Estrogen receptor | ||
| Vepdegestrant | Approved | Small molecule | Estrogen receptor | ||
| Camizestrant | Phase 3 | Small molecule | Estrogen receptor | ||
| Giredestrant | Phase 3 | Small molecule | Estrogen receptor | ||
| Palazestrant | Phase 3 | Small molecule | Estrogen receptor | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Anastrozole | Approved | Small molecule | Aromatase | ||
| Capecitabine | Approved | Small molecule | Fluoropyrimidine (antimetabolite) | ||
| Capivasertib | Approved | Small molecule | AKT (inhibitor) | ||
| Datopotamab Deruxtecan | Approved | Antibody–drug conjugate | TROP2 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Docetaxel | Approved | Small molecule | Microtubules (tubulin) |
…and 52 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
1 further head-to-head pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(27 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (5)
November 2026 (2)
December 2026 (3)
What to watch
What to watch
What to watch
2027 (6)
January 2027 (1)
What to watch
March 2027 (1)
What to watch
July 2027 (1)
What to watch
September 2027 (2)
October 2027 (1)
What to watch
2028 (9)
February 2028 (1)
What to watch
June 2028 (1)
What to watch
July 2028 (1)
What to watch
October 2028 (2)
November 2028 (1)
What to watch
December 2028 (3)
What to watch
What to watch
What to watch
2029 (4)
May 2029 (1)
What to watch
August 2029 (1)
What to watch
2031 (1)
August 2031 (1)
What to watch
2032 (1)
November 2032 (1)
What to watch
2033 (1)
September 2033 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.